Member Info for Yorkshireboy

Lots of great responses by Dan relating to questions which have obviously been uppermost in some investors’ minds, witnessed by their incessant posting. Hopefully, they will now cease, (at least for a few days) as they should realise that scientific research/development takes time.
Dan and the BoD are extremely aware of this, with over a decade of experience obtaining a multitude of existing ‘patents’ (which are probably the envy of quite a few major pharmaceutical organisations), that are now bearing fruition. Continuing to develop and secure additional (especially bespoke) ‘Intellectual Property’ (patents), whilst undertaking sensitive business negotiations takes time and skill. This expertise has been demonstrated proficiently by all, especially, Dan and Joanne who obtained their Chemistry PhDs in ‘Gods Country’, at the prestigious University of Leeds. I think there’s something special in the water up here in Yorkshire or it could have been the ‘Tetley’s Bitter’ which used to be brewed in Leeds and was pure ‘nectar’.
Nuformix is also special and if they can get on with their job, will also provide shareholders (who hold longer than two minutes) with barrel’s full of ‘dosh’.
I’ll drink to that, cheers all.

Cheers M1 that's great, a very good find. I was thinking that it may be Michael Reynolds at Morgan Stanley, Private Wealth Management (The Christensen Reynolds Group).
All the best.

Hi Mars1 many thanks for the link. I'm interested to know how you actually know that, Michael Reynolds is the founder of Ebers Tech and is at Merrill?
Thanking you in anticipation.
YB

Some posters may have previously seen this short promotional film, although it may be quite useful for new investors. It also provides a bit of light relief whilst waiting for update. However, I’m in no rush as, commercial/competitive protection/security is more important. Please see ‘whimax’ post this morning re 19th July podcast.
https://vimeo.com/236719945

Again, could this be an ideal match of the ‘rising sun to the rising star’! Pharmaceutical Research Analyst, Thomson Reuters in 2016 stated: - Japan has a longstanding relationship with immuno-oncology. In 1992, Japanese research scientists first discovered the programmed cell death-1 (PD-1) target. Since then, the T-cell receptor has received an influx of attention from drug developers seeking to use checkpoint inhibitors to stop cancer in its tracks.

Sorry, but I have now managed to overcome my initial melancholy and decided to go back to the hostelry for further refreshment. Buoyed by knowing I’m invested in such an unbelievably organisation who have a great team who are going to deliver (unlike England today) fantastic results.

Please be aware this is pure speculation on my part (fuelled by the odd dram), and you must do your own research. Although, I believe it is not beyond the realms of possibility and I’m in it for the long term. When I can happily retire in comfort, with a plentiful supply of good ‘Reds and Dalwhinnie, Winters Gold’! Which previously I could only dream off.

Please invest and drink responsibly.

Following the disappointing, but credible position of runner-up, in the Rugby World Cup. The tournament exceeded all expectations, especially the sublime organisation by a country named the ‘Land of the rising sun’. I then got to thinking is the ‘Land of the rising sun’ an ideal fit with NFX the ‘Bio-pharm rising star’! We should by now all know about The Kissei Group and its potential (Times) collaboration relating to Nuformix Patent: - Tranilast Compositions and Cocrystals.
Therefore, deciding not to watch the post-match, interviews, celebrations etc. I decided to investigate further and revisited the; RNS of 25 October 2019. This confirmed that the Company is in ‘discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme’. ‘The article was not about multiple potential licensees in Japan and Asia, Kissei was specifically (the only) company mentioned in the article. However, NFX ‘IP portfolio of granted patents covers cocrystal forms of five small molecule drugs, dating from 2010 onwards. Hence, as Dan et al are ‘theoretically negotiating’ with one Japanese company could there be other potential partner companies in Japan who would be a ‘good fit’ for other NFX Patents. Such as: -

Cilostazol cocrystals and compositions, WO US CN US8779146B2 Alan Chorlton Nuformix Limited
Priority 2010-04-28 • Filed 2011-04-28 • Granted 2014-07-15 • Published 2014-07-15
and
Rebamipide complexes and cocrystals, WO US CN HK US9248196B2 Joanne Holland Nuformix Limited
Priority 2011-02-25 • Filed 2012-02-24 • Granted 2016-02-02 • Published 2016-02-02

I decided to explore 2: -
OTSUKA Pharmaceutical, Japan, (Fiscal year 2018, Net Sales 554.1 Billion Japanese yen). Providing breakthrough treatments for patients around the world. Leveraging our research culture of curiosity, determination and unconventional thinking, and embracing close collaboration between our R&D institutes in Asia, the U.S. and Europe, we strive for solutions that only Otsuka can deliver. Our R&D philosophy encourages individual researchers to take untraveled paths, pursuing fresh ideas within a collaborative, accommodating environment, and ultimately creating novel solutions for patients worldwide and is associated with Cilostazol and Rebamipide medication.
and
NIPRO CORPORATION headquartered in Osaka, Japan, (Annual Report 2019, Year Ended March 31, 2019 Net sales: - 426,399 million of yen). Which is a leading global healthcare company dedicated to developing and delivering innovative and patient-oriented products for healthcare professionals, patients and pharmaceutical industry and is connected to Rebamipide medication.

In addition, I also looked at NFX Pre-Clinical pipeline: - NXP003: (Immuno-Oncology) which is sometimes overlooked due to its early development stage. However, Pre-clinical validation will support entry to the clinical pipeline and potential, Out-license/partner for further development.

Just read this and Valirx Plc is mentioned. Highlighted (*) below: -
'Bloomberg
Epigenetics Market Overview & Potential Growth Opportunities Report To 2025
29 October 2019, 09:20 GMT
The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025. Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases. Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.
*The key players* are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., *Valirx Plc*, and Sigma-Aldrich Corp.'
Browse 153 page research report with TOC on "Global Epigenetics Market" at: https://www.millioninsights.com/industry-reports/epigenetics-market-size

The discussion on this BB appears to focus on VAL 401 and 201, perhaps more in depth scrutiny should also be applied to VAL101 (GeneICE),
GeneICE “rebellious gene” technology continues to show good progress in the pre-clinical phase – the programme currently benefits from a second Eurostars grant for up to €1.6 million.
Rebellious genes are genes that are overexpressed or are erroneously expressed when they should not be, e.g. in cancers, inflammatory conditions, Alzheimer’s and autoimmune diseases. ValiRx’s proprietary GeneICE forward, ValiRx will look to leverage upon TRAC’s market presence and grow the sales of this diagnostic business. The Company believes that together with clinical validation, revenues from TRAC will grow, which will support both the biomarker and therapeutic development businesses. ValiFinn, which is itself already generating revenues, is well placed to further develop as a service/licensing business.
VAL101 is a novel therapeutic based on the Company’s proprietary GeneICE (Gene Inactivation by chromatin engineering) platform. It acts to target and switch “OFF” the gene that expresses Bcl-2, a protein that is implicated in about half of all carcinomas. Pre-clinical studies have established VAL101’s efficacy in prostate, ovarian and pancreatic cancers and it may also have anti-tumour activity against orphan oncologic indications. ValiRx’s GeneICE technology enables the selective silencing or the shutting down of particular rebellious genes, thereby halting and reversing tumour growth.
https://www.valirx.com/about-us/products-technology/

Please do your own research and have a good day, YB.

Following further investigation today, the above quote by Kammy (Chris Kamara) sprung to mind.

What an exceptional opportunity NFX are providing. Not only financially for investors, but enhanced treatment for patients who experience severe disabling and sometimes, life threatening conditions.

Reminder to self; top up again at first opportunity.

‘The focus of the Kissei Group is the manufacture and sale of ethical drugs, and the related materials. We are developing business activities such as purchase / sales, system development / information processing, construction contracting, facility / facility management, information gathering / development support service, and other services.
We aim to develop innovative pharmaceutical products that contribute to the improvement of medicine and the health of people around the world by aggressive incorporation of leading-edge technology and joint research and collaborations with our foreign and domestic partners.’
If the information is correct, especially the financial predictions i.e. Upfront milestone payments of £15 million and ANNUAL royalty payments worth more than £200 million (although there has been no mention of % of sales) then this is small change to a company of this size. With approx., Total Assets of over £1,530 million (Cash in Hand and in Banks over £188 million) and consolidated net annual sales of over £523 million, (Annual Report 2019 For the Year Ended March 31, 2019) if my conversion from the Japanese Yen is accurate.
If this deal happens and others follow, (which imo is a no brainer) including those previously highlighted then euphoria for all, except for those cashing in at such a low SP. Although, we must be patient as deals take time and we need to allow Dan and the BoD to continue to enable the excellent progress of this outstanding company.

Thanks roses, you're probably correct especially when 'buys' are reported incorrectly as 'sells', if this falsification continues it could result in the downward spiral of the SP. Don't want to create a conspiracy theory, but is it just accidental or is it intentional manipulation????

Good afternoon I’m a 1st time poster on this bb and obviously, there are varied opinions being posted reflecting the perceived current status of the company. These are all relevant as everyone is entitled to their own opinions. However, having monitored the company for some time and following my own examination, I have finally dipped my toe into the tepid pond, although, my ‘buy’ is being shown as a ‘sell’.
Though, I am expecting some disparaging remarks from some investors as to whether, I should have done so and do I require ‘treatment’! I realise that, unfortunately, several investors may be nursing a considerable loss, but for me it’s a balanced ‘punt’. Especially as they now have a healthier cash balance and outgoings are being reduced, I do believe there is a reasonable chance of success (albeit not immediately and will probably have to raise further capital) and for me, the potential financial reward, far exceeds any potential loss.
Good luck to all.

What were the board hoping for when offering, 2 for 1 share? Did they think it would detract from their ongoing incompetence and discombobulate investors into thinking that somehow, they are positively benefitting from the change. Even though any savvy share holder would see through this ruse as obviously the ‘deferred shares’ are valueless. Smoke and Mirrors comes to mind!

The decrease in ‘nominal value’ will not have any significant effect, but the ‘market value’ may be devalued by the issuing (the ‘placing’) of 142,857,143 ordinary shares in the capital of the company. This would mean an increase of over 40% of the current share issue in the capital of the Company. As this is a ‘Conditional Placing’, this and other resolutions require shareholder approval at a General Meeting. Why have we not been informed of a date since this has been in the planning since the publication of: -
Motif Bio Reports Half-Year 2019 Financial Results, Operational Progress and Proposed Initiatives. October 1, 2019. The pdf format is more informative than the News Release: -
ir.motifbio.com/node/8386/pdf
The section covering: - Proposed Corporate Restructuring and Loan Amendment (subject to shareholder approval) is extremely interesting and includes: -
‘Shareholders should be aware that there is no certainty that Motif Bio will be able to raise sufficient funding through the Proposed Capital Raise and that without such funding the Proposed Restructuring will not be put to shareholders at a general meeting for approval. If Motif Bio is unable to secure funding through the Proposed Capital Raise or otherwise, then it is expected that Motif Bio will no longer be able to continue operations and it is expected that trading in the Group's shares would be immediately suspended.’

I would advise all investors to read the PDF document, if they have not done so already and good luck to all.

Received the above communication, which includes: -

'Subject to shareholder approval at the Annual General Meeting, the company is proposing to subdivide its ordinary shares on the following basis.

Each existing ordinary share of GBP0.01 will be subdivided into 1 new ordinary share of GBP0.0001 and 1 Deferred valueless share of GBP0.0099.

Effective Date - To be advised.

Please note: The deferred shares will have only negligible rights and will therefore be effectively valueless. These will not be reflected in your account.'

Sorry for reasons unknown, it won't allow me to post the full web address.

Please go to 'Vox Markets' and search

The Vox Markets: - Anita Riotta Q&A with NFX CEO Dr Daniel Gooding 19th July 2019 interview is:-
****************************/listings/lon/nfx

In the videos Dan also referred to the first FDA-Approved Prescription Cannabidiol (CBD): - Epidiolex. A lead product developed by GW Pharmaceuticals (GWP). GWP is a biopharmaceutical company focused on discovering, developing and commercialising therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. They have also become the first firm to win European approval for a drug derived from the cannabis plant.
https://www.gwpharm.co.uk/healthcare-professionals/product-pipeline
https://www.macrotrends.net/stocks/charts/GWPH/gw-pharmaceuticals/market-cap
https://www.telegraph.co.uk/business/2019/07/26/britains-gw-pharmaceuticals-wins-first-eu-approval-cannabis/

The most common adverse reactions in patients receiving Epidiolex, include somnolence; decreased appetite; diarrhoea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.
Therefore, could it be an enhanced by a Nuformix Cocrystal? Cocrystal may be used in the same way as aprepitant to treat or prevent disorders relating to emesis, a neuropsychiatric disease, an inflammatory disease, pain, cancer, a skin disease, itch, a respiratory disease, or an addiction.
By the way GWP Headquarters are at Histon, Cambridge CB24 9BZ, which is just down the road from Nuformix HQ and their market cap, as of October 10, 2019 is $3.42B.

This is not investment advice or so called ‘ramping’, and clearly some is supposition from a simple lad (born in god’s country) passing time until, we receive news that everyone is looking forward to. In the meantime, please be patient and keep the faith in the excellent work of Dan et al.

Firstly, Manabouttown thanks for the reply to my request. Obviously, I can now put it into context as I thought ‘Dans reply’ which you initially posted could be viewed as a little challenging. In my opinion this was highly unusual as he’s always presented as being a gentleman who is extremely knowledgeable, professional and doing an outstanding job.
Since investing at the start of the year in NFX I have seen my originally investment increase over 350% at today’s share price, which is outstanding. Apparently, nothing can be guaranteed in life except for taxes and death, but I continue to top-up when I can (did so this morning) and look forward to my personal hypothesis being proved correct. With this phenomenon continuing over the next few years. When I might just cash in!
Though, I am invested and biased, I still try to present balanced views, and reading some of the BB comments, it appears certain investors want the ‘cream now’ and may not necessarily share my optimism. I am realistic regarding communication, and I believe this will come at the appropriate time which in a competitive environment is essential. As it shouldn’t allow any commercial advantage to would be competitors.
Therefore, it may be worthwhile for investors etc, to visit or revisit, a couple of video interviews, which may or may not answer some of their questions: -
Proactive’s Andrew Scott: - ‘Watershed moment' for Nuformix as it reports positive results for lead chemo drug.
30th May 2019
https://www.proactiveinvestors.co.uk/companies/news/313527/-watershed-moment--for-nuformix-as-it-reports-positive-results-for-lead-chemo-drug-13527.html
Vox Markets: - Anita Riotta Q&A with NFX CEO Dr Daniel Gooding 19th July 2019
****************************/listings/LON/NFX
Although they don’t necessarily cover the outstanding payment from New Summit Bio (NSB), they do mention the transition to Zhejiang Yatai Pharmaceutical (ZYP) which could be having an impact on this.
However, what has not been mentioned anywhere, is that ZYP in May 2019. Announced they had signed a definitive agreement to establish a joint venture company with Benchmark Botanics (BBT) a federally and multi-licensed diversified cannabis producer and distributor targeting the medical, pharmaceutical, and recreational markets in Canada and the EU.
https://www.newsfilecorp.com/release/46539/Benchmark-Botanics-Provides-Update-on-Investment-Cooperation-Agreement-with-Zhejiang-Yatai-Pharmaceutical
https://www.sedar.com/GetFile.do?lang=EN&docClass=8&issuerNo=00029441&issuerType=03&projectNo=02963993&docId=4586820
Is this something NFX has become involved in! If so, what a positive opportunity with their cannabinoid developments and collaborations in Canada.

Good evening SD78
It has no relevance if you are only here for the ‘money’ and although I agree that investors must be entitled to their own views. Many posters appear to be only concerned with the ‘Chinese payment’ and to me this has become tedious. Therefore, I wanted (like others have) to highlight that this is only one area (albeit important) to this innovative and exciting opportunity.

In addition, if you are one the investors who may be interested in other physiognomies of pharma-development, besides the personal pecuniary aspects. I decided to highlight the process and especially science (as mentioned in my post) behind this first collaborative milestone achievement (hopefully one of many) with ‘Ebers’. If people take the time to read the documents fully, they will appreciate the intricacies and progress required for patent development and should also realise that the first filing was September 2010 and monitors the history to the last $200 fee payment on 13/09/2019 etc.

In the September RNS it was stated: -
‘Nuformix and Ebers are pleased to announce a first patent filing in relation to novel cannabinoid cocrystals following the commencement of development activities under the previously announced Strategic Cannabinoid Agreement (the "Agreement").
Under the Agreement, Ebers gained exclusive access to Nuformix's existing cannabinoid IP and technology platforms to enable the development of differentiated cannabinoid products. This first resulting patent filing relates to novel forms of a naturally occurring cannabinoid, which is the subject of growing scientific interest as its therapeutic promise becomes increasingly validated. The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, which in due course, will generate further milestone payments, plus royalties to Nuformix of 20% under the Agreement terms.
Nigel Little, Director of Ebers, said: "We're excited Nuformix have achieved this first patent filing for Ebers Tech. From a strategic perspective, Nuformix's proven track-record in securing worldwide patent protection for improved drug forms provides Ebers with an opportunity to generate high-value IP, identified as a limitation within the emerging cannabinoid market. This a key milestone in allowing Ebers to create and protect superior cannabinoid products for consumer product and therapeutic applications.
Dr Dan Gooding, CEO, Nuformix plc, added: "We're delighted to secure this opening cannabinoid IP filing, which serves as the first disclosable validation of the Ebers agreement. The number of patents filed is one of several key performance indicators for the collaboration and demonstrates the partnership and overall concept are well-founded. For Nuformix, this first patent filing creates a path to further income from Ebers. We will continue to inform the market as further patents are filed and milestones and royalties are paid in-line with the agreement.'

This is an outstanding strategic partnership for the organisation, investors (both financial and/or altruistic) and people who experience debilitating disorders. For those who are interested in ‘patents’, the following is from the ‘Canadian Intellectual Property Office’. If this is not enough, the 2nd link is to some supplementary light bedtime reading relating to the science.

APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL
Patent CA 2846460
Issued: 2019-01-08
The 1:1:1 aprepitant L-proline H20 composition or cocrystal may be used in the same way as aprepitant to treat or prevent disorders relating to emesis, a neuropsychiatric disease, an inflammatory disease, pain, cancer, a skin disease, itch, a respiratory disease, or an addiction.
www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html

https://patents.google.com/patent/CA2846460A1/en
Have a good day.

https://audioboom.com/posts/7374848-the-weekend-podcast